首页> 外文OA文献 >The effect of ACTH4-10Pro8Gly9Pro10 and HMG-CoA reductase inhibitor in moderate head injury: clinical outcome and serum Bcl-2 concentration
【2h】

The effect of ACTH4-10Pro8Gly9Pro10 and HMG-CoA reductase inhibitor in moderate head injury: clinical outcome and serum Bcl-2 concentration

机译:acth 4-10s pro 8℃ 9 pro 10 和hmg-coa还原酶抑制剂中的效果损伤:临床结果和血清BCL-2浓度

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: An important component of brain tissue damage is apoptotic neuronal death. Bcl-2 is an anti-apoptotic protein, which inhibits the intrinsic pathway of apoptosis. ACTH4-10Pro8Gly9Pro10 and HMG-CoA reductase inhibitor are known for their neuroprotective effects. This study aimed to compare the effect of standard therapy, ACTH4-10Pro8Gly9Pro10, and HMG-CoA reductase inhibitor (simvastatin 40 mg/day) on serum Bcl-2 levels, clinical outcome, and reduction of hospital stay.Methods: Sixty subjects with moderate head injury without any indication for surgery were taken consecutively and separated into three groups: standard treatment only (control group), standard treatment combined with ACTH4-10Pro8Gly9Pro10, and standard treatment combined with inhibitor of HMG-CoA reductase. Blood samples were taken on day-1 and day-5 from each subject for measurement of Bcl-2 concentration. Barthel Index and MMSE were measured at discharge and hospital length of stay was noted. Difference in mean was analyzed with one way ANOVA and correlation between Bcl-2 and clinical outcome was measured with Pearson correlation test.Results: Bcl-2 serum levels on day-1 and day-5 were tespectively as follows: in control group were 1.39 ± 0.75 and 1.48 ± 0.77 ng/mL; in ACTH4-10Pro8Gly9Pro10 group 1.39 ± 0.70 and 3.70 ± 1.01 ng/mL which was significantly higher compared to other groups and associated with the shortest length of stay. In simvastatin group, 1.53 ± 0.55 and 2.17 ± 0.56 ng/mL. We found the length of stay in the ACTH4-10Pro8Gly9Pro10 group to be significantly shorter (p < 0.001). The correlation of clinical outcome (Barthel index and MMSE) with serum Bcl-2 levels was not significant.Conclusion: ACTH4-10Pro8Gly9Pro10 significantly increased serum Bcl-2 concentration in head injury and associated with shorter length of stay. An increase of serum Bcl-2 concentration was also found in simvastatin group, but it was not significant. (Med J Indones. 2013;22:221-6. doi: 10.13181/mji.v22i4.604)Keywords: ACTH4-10Pro8Gly9Pro10, Bcl-2, traumatic brain injury
机译:背景:脑组织损伤的重要组成部分是凋亡神经元死亡。 Bcl-2是一种抗凋亡蛋白,其抑制细胞凋亡的内在途径。 ACTH4-10PRO8GLY9PRO10和HMG-COA还原酶抑制剂是其神经保护作用。本研究旨在比较标准治疗,ACTH4-10PRO8GLY9PRO10和HMG-COA还原酶抑制剂(SIMVASTATIN 40mg /天)对血清BCL-2水平,临床结果和减少住院入住的疗效。方法:60个受试者中度没有任何手术指示的头部损伤连续,分为三组:仅限标准治疗(对照组),标准处理与ACTH4-10PRO8GLY9PRO10联合,标准处理与HMG-COA还原酶的抑制剂联合。从每次受试者拍摄血液样品,从每个受试者中测量Bcl-2浓度。在放电和医院住院时间内测量条形点指数和MMSE。用一种方式分析平均值的差异,并用Pearson相关试验测量Bcl-2与临床结果之间的相关性。结果:Day-1和Day-5的Bcl-2血清水平如下:对照组是1.39 ±0.75和1.48±0.77 ng / ml;在Acth4-10Pro8Gly9Pro10组中,与其他组相比,3.39±0.70和3.70±1.01 ng / ml显着更高,并且与最短的逗留时间相关联。在辛伐他汀组中,1.53±0.55和2.17±0.56 ng / ml。我们发现ACTH4-10PRO8GLY9PRO10组的逗留时间明显缩短(P <0.001)。临床结果(条形指数和MMSE)与血清BCL-2水平的相关性并不显着。结论:Conth4-10Pro8Gly9Pro10显着增加头部损伤中的血清Bcl-2浓度,并且保持较短的逗留时间。在辛伐他汀组中也发现了血清BCl-2浓度的增加,但它不显着。 (MED J Indones。2013; 22:221-6。DOI:10.13181 / MJI.v22i4.604)关键词:ACTH4-10PRO8GLY9PRO10,BCL-2,创伤性脑损伤

著录项

  • 作者

    Suzy Indharty;

  • 作者单位
  • 年度 2013
  • 总页数
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号